Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4692005

Cn1ccc2c3c(N)nc(N)nc3cc(-c3cccc(Cl)c3)c21.O=C(O)C(F)(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.41
DHFR P00374 5/20 0.39
C1S P09871 1/20 0.38
SLC2A1 P11166 2/20 0.37
LTB4R Q15722 1/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ATM Q13315 4/20 0.36
MET P08581 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4691346 0.92 DHFR (0.41) MAP4K4DHFRC1SSLC2A1MET
Trifluoroacetic Acid SCHEMBL4693910 0.91 DHFR (0.41) DHFRSLC2A1
SCHEMBL4689899 0.90 MAP4K4 (0.49) MAP4K4DHFRSLC2A1
Trifluoroacetic Acid SCHEMBL4687967 0.90 SLC2A1 (0.41) DHFRSLC2A1NPC1RAB9A
Trifluoroacetic Acid SCHEMBL4689915 0.90 SLC2A1 (0.41) DHFRSLC2A1
Trifluoroacetic Acid SCHEMBL4692155 0.90 DHFR (0.40) DHFRSLC2A1
Trifluoroacetic Acid SCHEMBL4693908 0.90 DHFR (0.41) MAP4K4DHFRSLC2A1LTB4RMET
Trifluoroacetic Acid SCHEMBL4692244 0.89 DHFR (0.42) DHFRSLC2A1
Trifluoroacetic Acid SCHEMBL4690937 0.88 DHFR (0.52) DHFRSLC2A1
Trifluoroacetic Acid SCHEMBL4692099 0.88 DHFR (0.39) DHFRSLC2A1MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1628979-B1 DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS HOFFMANN LA ROCHE (CH) 2008-03-19 EP disclosed
US-20070270445-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors BERTHEL STEVEN J 2007-11-22 US disclosed
US-7262297-B2 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors HOFFMANN-LA ROCHE INC. (US) 2007-08-28 US disclosed
US-20040235872-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors BERTHEL STEVEN JOSEPH (US) 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235872-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors PTPN5, PPP5C, PTP4A2 MAP4K4 182/4885DHFR 289/4885C1S 4806/4885
US-20070270445-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors PTPN5, DUSP15, PPP5C MAP4K4 192/4885DHFR 339/4885C1S 4853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.